Victoria Richards, associate professor of medical sciences in the Frank H. Netter MD School of Medicine at Quinnipiac University, is available to discuss simeprevir, a new drug for treating hepatitis C that a Food and Drug Administration Advisory Committee is scheduled to consider for approval at a meeting on Oct. 24.
“It will be very interesting to see if the FDA approves simeprevir, a protease inhibitor with potent antiviral properties against hepatitis C virus (HCV) genotype 1, the genotype that dominates in the Americas,” said Richards, who holds a PhD in pharmacology and toxicology. “Typical therapy for Hep C includes peginteferon, ribavirin and a protease inhibitor. But, in contrast to other protease inhibitors, simeprevir can be given orally, once daily instead of three times a day and does not seem to cause the same adverse skin reactions at the same frequency. According to the data for patients who had not received treatment before, when simeprevir was added to peginteferon and ribavirin, there was an 80% improvement in efficacy over peginteferon/ribavirin alone. Also, the rate of response to therapy (undetectable levels of the virus) was 80%. If it is approved by the FDA, this would be an important addition to the tool-box of treatments for Hep C.”
To speak to Richards, please call John Morgan, associate vice president for public relations, at 203-206-4449 (cell) or 203-582-5359 (office).